DRTS 6-K: SEC filing

Alpha Tau Medical

Filed with the SEC on Nov 12, 2026 · accession 0001213900-26-118478

DRTS filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. Alpha Tau Medical announced it will host an investor call to review new data from the Alpha DaRT Recurrent Glioblastoma REGAIN Trial.

Summary of the filing

Alpha Tau Medical announced it will host an investor call to review new data from the Alpha DaRT Recurrent Glioblastoma REGAIN Trial. The announcement was made via a press release attached to a Form 6-K filing.

For details, click here →How to read a 6-K →

Key details

RegistrantAlpha Tau Medical Ltd.

Chief executive officerUzi Sofer

✦ Ask GOAX AI about this filing — what it means for DRTS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRTS?

Click here

Frequently asked questions

What did DRTS file with the SEC on Nov 12, 2026?

DRTS filed a 6-K (SEC filing). Alpha Tau Medical announced it will host an investor call to review new data from the Alpha DaRT Recurrent Glioblastoma REGAIN Trial. The announcement was made via a press release attached to a Form 6-K filing.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other DRTS SEC filings

Get alerts when DRTS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

DRTS overview DRTS analysis DRTS news Latest SEC filings